Clinical & Economic Outcomes of Outpatient Parenteral Antimicrobial Therapy among Indigent Patients

SAN FRANCISCO, CA (October 4, 2013) – This study is a report of clinical and economic outcome data of a hospital-funded Indigent Healthcare Program conducted in 11 Infectious Disease (ID) Physician Office Infusion Centers (POICs) during 2012. The Indigent Healthcare Program allowed uninsured patients to discharge from the hospital and continue intravenous antimicrobial therapy in an ID POIC. A total of 90 patients received intravenous antibiotics (IVAB) following hospital discharge. Patients had a wide range of diagnoses with bone and joint infections predominant (42%) followed by complicated skin and skin structure infections (18%). Methicillin-sensitive S. aureus was the infecting pathogen in 24% followed by Methicillin-resistant S. aureus in 18%. Adverse drug events were reported in 19 patients (21%), but no discontinuation of antibiotics was necessary. Ninety-three percent of patients had a successful clinical outcome, of which 73% were cured (no evidence of infection) and 20% improved with either partial resolution of signs and symptoms or switch to oral therapy. The estimated daily cost per POIC patient was $174. In comparison, the national estimate for the same hospital stay would be $2,189 per day. As a result, the average cost per patient using OPAT via POIC were reduced by $2,015 per day or 76% of inpatient hospital costs. Overall cost savings achieved were $43,292 per patient and $3.9 million for all patients. This study indicates that OPAT via an ID POIC enabled non-resource patients with infectious diseases to receive high-quality, patient-centered care, with a significant reduction in health care costs. To learn more, click here.

This study was orally presented at the 2nd annual IDWeek™.

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

ABOUT IDWeek 2013
IDWeek 2013 is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2013 took place October 2-6 at the Moscone Center in San Francisco, California. For more information, visit www.idweek.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.